Phosphomannopentaose sulfate (PI-88) inhibits retinal leukostasis in diabetic rat

Biochemical and Biophysical Research Communications

Volumn 380, Issue 2, 2009, Pages 402-406

  Ma, Pingping ^a   Luo, Yan ^a   Zhu, Xiaobo ^a   Ma, Hongjie ^a   Hu, Jie ^a   Tang, Shibo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diabetic retinopathy; Intracellular adhesion molecule (ICAM) 1; Leukostasis; Phosphomannopentaose sulfate (PI 88); Rat; Vascular endothelial cell growth factor (VEGF)

Indexed keywords

CD45 ANTIGEN; CONCANAVALIN A; INTERCELLULAR ADHESION MOLECULE 1; PI 88; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG MECHANISM; DRUG SCREENING; ELECTRORETINOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; LEUKOCYTE; LEUKOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; RAT; RETINA DISEASE; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOWN-REGULATION; ELECTRORETINOGRAPHY; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; LEUKOSTASIS; OLIGOSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 60349094082     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.092     Document Type: Article

References (36)

1. Moss S.E., Klein R., and Klein B.E. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105 (1998) 998-1003
2. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris III F.L., and Klein R. Diabetic retinopathy. Diabetes Care 21 (1998) 143-156
3. Miyamoto K., Hiroshiba N., Tsujikawa A., and Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. 39 (1998) 2190-2194
4. Joussen A.M., Poulaki V., Le M.L., Koizumi K.., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., and Adamis A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18 (2004) 1450-1452
5. Chibber R., Ben-Mahmud B.M., Chibber S., and Kohner E.M. Leukocytes in diabetic retinopathy. Curr. Diabetes Rev. 3 (2007) 3-14
6. McLeod D.S., Lefer D.J., Merges C., and Lutty G.A. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroids. Am. J. Pathol. 147 (1995) 642-653
7. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.E., and Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 158 (2001) 147-152
8. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., Aiello L.P., Ogura Y., and Adamis A.P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. USA 96 (1998) 10836-10841
9. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S., Hida T., Oguchi Y., and Adamis A.P. VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2155-2162
10. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., Rudge J., Yancopoulos G.D., and Adamis A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 160 (2002) 501-509
11. Miyamoto K., Khosrof S., Bursell S.E., Moromizato Y., Aiello L.P., Ogura Y., and Adamis A.P. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am. J. Pathol. 156 (2000) 1733-1739
12. Lu M., Perez V.L., Ma N., Miyamoto K., Peng H.B., Liao J.K., and Adamis A.P. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest. Ophthalmol. Vis. Sci. 40 (1999) 1808-1812
13. Kudchadkar R., Gonzalez R., and Lewis K.D. PI-88: a novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 17 (2008) 1769-1776
14. Ferro V., Dredge K., Liu L., Hammond E., Bytheway I., Li C., Johnstone K., Karoli T., Davis K., Copeman E., and Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 33 (2007) 557-568
15. Jensen R.L. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg. Neurol. 49 (1998) 189-195
16. Le Querrec A., Duval D., and Tobelem G. Tumour angiogenesis. Baillieres Clin. Haematol. 6 (1993) 711-730
17. Karoli T., Liu L., Fairweather J.K., Hammond E., Li C.P., Cochran S., Bergefall K., Trybala E., Addison R.S., and Ferro V. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J. Med. Chem. 48 (2005) 8229-8236
18. Khachigian L.M., and Parish C.R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc. Drug Rev. 22 (2004) 1-6
19. Demir M., Iqbal O., Hoppensteadt D.A., Piccolo P., Ahmad S., Schultz C.L., Linhardt R.J., and Fareed J. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin. Appl. Thromb. Hemost. 7 (2001) 131-140
20. Lewis K.D., Robinson W.A., Millward M.J., Powell A., Price T.J., Thomson D.B., Walpole E.T., Haydon A.M., Creese B.R., Roberts K.L., Zalcberg J.R., and Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 26 (2008) 89-94
21. Levidiotis V., Freeman C., Punler M., Martinello P., Creese B., Ferro V., van der Vlag J., Berden J.H., Parish C.R., and Power D.A. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J. Am. Soc. Nephrol. 15 (2004) 2882-2892
22. Parish C.R., Freeman C., Brown K.J., Francis D.J., and Cowden W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59 (1999) 3433-3441
23. Francis D.J., Parish C.R., McGarry M., Santiago F.S., Lowe H.C., Brown K.J., Bingley J.A., Hayward I.P., Cowden W.B., Campbell J.H., Campbell G.R., Chesterman C.N., and Khachigian L.M. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ. Res. 92 (2003) e70-e77
24. Mamputu J.C., and Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J. Leukoc. Biol. 75 (2004) 1062-1069
25. Hirata F., Yoshida M., and Ogura Y. High glucose exacerbates neutrophil adhesion to human retinal endothelial cells. Exp. Eye Res. 82 (2006) 179-182
26. Miyamoto K., and Ogura Y. Diabetic retinopathy and leukocytes-feasibility of anti-leukostasis therapy for diabetic retinopathy. Nippon Rinsho 60 (2002) 183-188
27. Miyamoto K., and Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin. Ophthalmol. 14 (1999) 233-239
28. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., and Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc. Res. 72 (2006) 86-90
29. Ferro V., Fewings K., Palermo M.C., and Li C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88. Carbohydr. Res. 332 (2001) 183-189
30. Yu G., Gunay N.S., Linhardt R.J., Toida T., Fareed J., Hoppensteadt D.A., Shadid H., Ferro V., Li C., Fewings K., Palermo M.C., and Podger D. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur. J. Med. Chem. 37 (2002) 783-791
31. Nyberg K., Ekblad M., Bergström T., Freeman C., Parish C.R., Ferro V., and Trybala E. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antiviral Res. 63 (2004) 15-24
32. Lee E., Pavy M., Young N., Freeman C., and Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 69 (2006) 31-38
33. Xu X., Rao G., Quiros R.M., Kim A.W., Miao H.Q., Brunn G.J., Platt J.L., Gattuso P., and Prinz R.A. In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas, loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J. Biol. Chem. 282 (2007) 2363-2373
34. Cochran S., Li C., Fairweather J.K., Kett W.C., Coombe D.R., and Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J. Med. Chem. 46 (2003) 4601-4608
35. Vlodavsky I., Ilan N., Naggi A., and Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 13 (2007) 2057-2073
36. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., and Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 66 (2006) 1455-1463